The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

por Harrington, Kimberly H., Gudgeon, Chelsea J., Laszlo, George S., Newhall, Kathryn J., Sinclair, Angus M., Frankel, Stanley R., Kischel, Roman, Chen, Guang, Walter, Roland B.
Publicado 2015

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

por Gong, Yixuan, Yao, Evelyn, Shen, Ronglai, Goel, Aviva, Arcila, Maria, Teruya-Feldstein, Julie, Zakowski, Maureen F., Frankel, Stanley, Peifer, Martin, Thomas, Roman K., Ladanyi, Marc, Pao, William
Publicado 2009

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia

por Subklewe, Marion, Topp, Max, Krupka, Christina, Kufer, Peter, Kischel, Roman, Köhnke, Thomas, Baeuerle, Patrick, Zugmaier, Gerhard, Frankel, Stanley, Maniar, Tapan, Newhall, Katie, Spiekermann, Karsten, Riethmueller, Gert, Nagorsen, Dirk, Hiddemann, Wolfgang
Publicado 2014

Target discovery for T cell therapy: next steps to advance Immunotherapies

por Bot, Adrian, Brewer, Joanna E, Eshhar, Zelig, Frankel, Stanley R, Hickman, Emma, Jungbluth, Achim A, Morgan, Richard, Peretz, Yoav, Radvanyi, Laszlo, Ramos, Carlos A, Robbins, Paul F, Wucherpfennig, Kai W
Publicado 2015